Epigenetic regulation of inflammation: Progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs

Melissa Cantley, David R. Haynes

Research output: Contribution to journalReview articlepeer-review

51 Citations (Scopus)


Inhibition of histone deacetylases (HDAC) is emerging as a novel approach to treat a variety of diseases. Recently, broad acting inhibitors of HDAC have been shown to have anti-inflammatory effects both in vitro and in vivo. It is significant that these anti-inflammatory effects are observed at 10-100 fold lower concentrations than their anti-cancer effects. The broad action of these compounds makes it difficult to determine which HDAC enzymes are important in inflammation. Although showing promise it is unlikely that these drugs will progress to the clinic for treating inflammatory diseases due to number of HDACs they affect and the widespread activity of the enzymes throughout the body. Accordingly, research is now progressing to targeting specific HDAC enzymes to improve efficacy of treatment as well as reduce the risk of any unwanted side effects. Understanding the role specific HDACs play in inflammatory disease will help us to identify novel anti-inflammatory treatments. This manuscript is designed to review our limited knowledge in this field.

Original languageEnglish
Pages (from-to)301-307
Number of pages7
Issue number4
Publication statusPublished or Issued - 1 Aug 2013
Externally publishedYes


  • Anti-inflammatory treatments
  • Histone deacetylase inhibitors
  • Inflammation

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Pharmacology (medical)

Cite this